Targeted delivery of chemotherapeutics and diagnostic agents conjugated to carrier ligands
has made significant progress in recent years, both in regards to the structural design of the …

Targeted drug delivery to specific group of cells offers an attractive strategy to minimize the
undesirable side effects and achieve the therapeutic effect with a lower dose. Both linear …

Cancer remains the leading cause of death worldwide despite advances in treatment
options for patients. As such, safe and effective therapeutics are required. Short peptides …

Drug delivery systems are generally believed to comprise drugs and excipients. A peptide–
drug conjugate is a single molecule that can simultaneously play multiple roles in a drug …

Drug conjugates have become a significant focus of research in the field of targeted
medicine for cancer treatments. Peptide-drug conjugates (PDCs), a subset of drug …

The emergence of peptide–drug conjugates (PDCs) that utilize target-oriented peptide
moieties as carriers of cytotoxic payloads, interconnected with various cleavable …

Most toxic agents currently used for chemotherapy show a narrow therapeutic window,
because of their inability to distinguish between healthy and cancer cells. Targeted drug …

Efficient intracellular trafficking and targeted delivery to the site of action are essential to
overcome the current drawbacks of cancer therapeutics. Cell Penetrating Peptides (CPPs) …

More than 100 years ago, German physician Paul Ehrlich first proposed the concept of
selectively delivering “magic bullets” to tumors through targeting agents. The targeting …

Cancer is the second leading cause of death affecting nearly one in two people, and the
appearance of new cases is projected to rise by> 70% by 2030. To effectively combat the …